10-Q: Twist Bioscience Reports Strong Revenue Growth in Q1 2025, Gross Margin Improves

Twist Bioscience saw a 24% increase in revenue and improved gross margins in the first quarter of fiscal year 2025, driven by growth in NGS tools and synthetic genes.

Summary

• Twist Bioscience reported a 24% increase in revenue, reaching $88.7 million for the quarter ended December 31, 2024, compared to $71.5 million in the same period of 2023.
• The company's gross margin improved to 48.3% from 40.5% year-over-year, primarily due to increased revenue and the spreading of fixed costs.
• The loss from operations decreased to $34.6 million from $47.0 million year-over-year, reflecting the positive impact of revenue growth and improved gross profit.
• Net loss per share improved to $0.53 from $0.75 year-over-year.
• Net cash used in operating activities decreased to $21.4 million from $23.0 million year-over-year.
• The company shipped approximately 205,000 genes in the quarter, a 20% increase compared to the 171,000 genes shipped in the same period of 2023.
• Twist Bioscience had approximately 3,562 customers annually and 2,376 customers in the current quarter.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved gross margins, which are positive indicators. However, the company is still operating at a loss and faces risks, which temper the overall sentiment. The $15 million upfront payment is a positive development.

Positives

• The company experienced strong revenue growth of 24% year-over-year.
• Gross margin improved significantly, indicating better cost management and pricing.
• The company reduced its operating losses compared to the same period last year.
• Net loss per share improved, showing progress towards profitability.
• The company reduced its cash burn from operations.
• The number of genes shipped increased by 20% year-over-year, demonstrating increased production and demand.
• The company secured a $15 million upfront payment, strengthening its financial position.

Negatives

• The company continues to operate at a loss, with a net loss of $31.6 million for the quarter.
• The company has an accumulated deficit of $1,273.5 million.
• The company's cash and cash equivalents decreased to $221.4 million from $226.3 million in the previous quarter.
• Interest income decreased by 21% due to lower cash and investment balances.

Risks

• The company's ability to achieve profitability depends on the success of its existing products and the development of new products.
• The company faces risks related to competition, technology changes, and the ability to manage growth.
• The company's future performance is subject to economic and market conditions.
• The company is involved in a securities class action lawsuit and a derivative action, which could result in significant costs and liabilities.
• The company's estimates of future milestone and royalty payments are subject to change, which could impact the liability related to the sale of future revenue.

Future Outlook

The company expects that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations for at least one year from the date the financial statements are issued. The company's ability to generate product revenue sufficient to achieve profitability will depend heavily on the success of its existing products and the development and commercialization of additional products in the synthetic biology, biologic drug and data storage industries as well as leveraging its investment in its manufacturing facility in Wilsonville, Oregon.

Management Comments

• The company believes its products enable a broad range of applications that may ultimately improve health and the sustainability of the planet across multiple industries.
• The company's easy-to-use e-commerce platform allows customers to design, validate, and place on-demand orders of customized DNA online, and enables them to receive real-time customized quotes for their products and track their order status through the manufacturing and delivery process.

Industry Context

The company's growth in revenue and gross margin reflects the increasing demand for synthetic biology tools and services. The company's focus on NGS tools and antibody discovery aligns with broader trends in the healthcare and biotechnology industries. The company's expansion into new markets such as synthetic RNA and digital data storage positions it to capitalize on future growth opportunities.

Comparison to Industry Standards

• Twist Bioscience's revenue growth of 24% is strong compared to some of its peers in the synthetic biology space, although direct comparisons are difficult due to varying business models and product focuses.
• The improvement in gross margin to 48.3% is a positive sign, indicating better cost management and pricing power, which is crucial for long-term sustainability.
• Companies like Ginkgo Bioworks and Amyris also operate in the synthetic biology space, but their financial results and business models differ significantly, making direct comparisons challenging.
• Twist's focus on DNA synthesis and NGS tools positions it well in the market, but it faces competition from established players in these areas.
• The company's investment in its manufacturing facility in Wilsonville, Oregon, is a strategic move to increase production capacity and reduce costs, which is a common strategy among companies in this industry.

Legal Proceedings

• The company is involved in a securities class action lawsuit and a derivative action, both related to allegations made in a report issued by Scorpion Capital.
• The company has filed a motion to dismiss the amended complaint in the securities class action lawsuit and is awaiting the judge's decision.

Related Party Transactions

• The company had revenues from related parties of $4.0 million and $2.3 million for the three months ended December 31, 2024 and 2023, respectively.
• Receivable balances with related parties were $0.7 million and $0.5 million as of December 31, 2024 and September 30, 2024, respectively.

Stakeholder Impact

• Shareholders will be encouraged by the revenue growth and improved gross margins, but concerned about the ongoing losses and legal proceedings.
• Employees may be positively impacted by the company's growth and expansion, but also concerned about the company's financial stability.
• Customers will benefit from the company's expanding product offerings and improved manufacturing capabilities.
• Suppliers may see increased demand for their products as the company grows.
• Creditors will be monitoring the company's financial performance and ability to repay its debts.

Next Steps

• The company will continue to focus on increasing revenue and improving profitability.
• The company will continue to develop and commercialize new products in the synthetic biology, biologic drug, and data storage industries.
• The company will continue to leverage its investment in its manufacturing facility in Wilsonville, Oregon.

Key Dates

Keywords

synthetic biology, DNA synthesis, NGS tools, antibody discovery, biopharma, revenue growth, gross margin, financial results, gene synthesis, biologic drugs